ArticleChronic diseases and translational medicine2020
Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic.
Article in Chronic diseases and translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Covid-19 (Sars-Cov-2 Infection) Information for Patients with Predialytic Chronic Kidney Disease.Jornal brasileiro de nefrologia · 2020Guideline
- Hemodialysis equipment malfunction incidence and risk profiling in clinical settings: a retrospective single-center cohort analysis.Biomedical engineering online · 2025Article
- Chronic kidney disease in the shadow of COVID-19: insights from the bibliometric analysis.International urology and nephrology · 2024Article
- Article
- COVID-19 infection and severe clinical outcomes in patients with kidney disease by vaccination status: a nationwide cohort study in Korea.Epidemiology and health · 2024Article
- A Study on Mortality Predictors in Hemodialysis Patients Infected with COVID-19: Impact of Vaccination Status.Vaccines · 2023Article
- Impact of the COVID-19 pandemic on access to healthcare, physical and mental health among patients with chronic kidney disease in Victoria, Australia.International urology and nephrology · 2023Article
- Clinical manifestations of COVID-19 infection in dialysis patients and protective effect of COVID-19 vaccine.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Review
- Narrative review on century of respiratory pandemics from Spanish flu to COVID-19 and impact of nanotechnology on COVID-19 diagnosis and immune system boosting.Virology journal · 2022Review
- The Pharmacist's Role in Managing COVID-19 in Chronic Kidney Disease Patients: A Review of Existing Strategies and Future Implications.Pharmacy (Basel, Switzerland) · 2022Review
- Spectrum of Kidney Injury Following COVID-19 Disease: Renal Biopsy Findings in a Single Italian Pathology Service.Biomolecules · 2022Article
- Global health emergencies during the pandemic and their solutionsTurkish journal of medical sciences · 2021Review
- COVID-19 in dialysis units: A comprehensive review.World journal of virology · 2021Review
- Predictors of mortality of COVID-19 in the general population and nursing homes.Internal and emergency medicine · 2021Article
- The emergency department care for hemodialysis patient during the COVID-19 pandemic.The American journal of emergency medicine · 2021Review
- Anticoagulation therapy in COVID-19 patients with chronic kidney disease.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2021Review
- COVID-19 pandemic: The role of community pharmacists in chronic kidney disease management supportive care.Research in social & administrative pharmacy : RSAP · 2021Article
- Investigation on anxiety and depression of different populations in the area with low incidence of New Coronavirus pneumonia and analysis of related factors.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 has become a pandemic and it has already spread to at least 171 countries/regions. Chronic kidney disease (CKD) is a global public health problem with a total of approximately 850 million patients with CKD worldwide and 119.5 million in China. Severe COVID-19 infection may damage the kidney and cause acute tubular necrosis, leading to proteinuria, hematuria and elevated serum creatinine. Since the SARS-CoV-2 enters the cells by binding to the angiotensin-converting enzyme 2 receptor, some doctors question its ability to increase the risk and severity of developing COVID-19. Neither clinical data nor basic scientific evidence supports this assumption. Therefore, patients who take angiotensin-converting enzyme inhibitor or angiotensin receptor blocker are not advised to change their therapy. Patients with CKD are generally the elderly population suffering from multiple comorbidities. Moreover, some patients with CKD might need to take glucocorticoids and immunosuppressants. Dialysis patients are recurrently exposed to a possible contaminated environment because their routine treatment usually requires three dialysis sessions per week. Considering all the above reasons, patients with CKD are more vulnerable to COVID-19 than the general population. The development of COVID-19 may worsen the impaired kidney function and further lead to rapid deterioration of kidney function and even death. Strict comprehensive protocols should be followed to prevent the spread of COVID-19 among patients with CKD. In this review, we provide some practical management recommendations for health care providers, patients with CKD, dialysis patients and dialysis facilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.